Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study. 2021

Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
Department of Neurology, Sijhih Cathay General Hospital, New Taipei City, Taiwan.

BACKGROUND The use of dihydropyridine calcium channel blockers (DCCBs) was proposed to reduce the risk of Parkinson's disease (PD). This study aimed to evaluate the association between DCCB and its dose effect and the risk of PD in patients with newly diagnosed hypertension. METHODS This population-based retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension, between 2001 and 2013, from Taiwan's National Health Insurance Research Database. Patients who had PD before hypertension or were taking antipsychotics for more than 30 days in the 6 months prior to the end of the observation period were excluded. A Cox proportional hazard model was used to estimate the risk of PD in different groups. The dose-related effects of DCCB on the risk of PD were evaluated according to the cumulative defined daily dose (DDD). RESULTS We observed 832 (1.2%) PD cases in patients treated with DCCB as compared to 950 (2.4%) PD cases in those not treated with DCCB, during a median follow-up duration of 8.3 years and 6.2 years, respectively. The risk of PD in the DCCB-treated group (hazard ratio [HR] = 0.50) was significantly lower than that in the group without DCCB treatment. DCCB reduced the risk of PD in a dose-dependent manner, with HRs ranging from 0.61 to 0.37 for DDDs of 90-180 to >720. CONCLUSIONS DCCB treatment was associated with a significantly reduced risk of PD in patients with newly diagnosed hypertension. Further clinical trials are needed to confirm the proposed neuroprotective effects of DCCB in PD.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence

Related Publications

Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
January 2015, International journal of chronic diseases,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
December 2022, Journal of the American Heart Association,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
July 2016, Epidemiology (Cambridge, Mass.),
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
January 2018, PloS one,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
January 2017, PeerJ,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
January 2015, The Journal of clinical psychiatry,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
February 2018, Parkinsonism & related disorders,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
January 2022, Frontiers in pharmacology,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
September 2020, BMC neurology,
Yuan-Fu Tseng, and Hsiu-Chen Lin, and Jane Chen-Jui Chao, and Chien-Yeh Hsu, and Hsiu-Li Lin
March 1998, BMJ (Clinical research ed.),
Copied contents to your clipboard!